DCPrime, Janssen in Vax Research Alliance

DCPrime BV has entered into a research and optional license agreement with Janssen Pharmaceuticals, in conjunction with the Johnson & Johnson London Innovation Centre, where a team of business and science members identify and build novel early-stage collaborations with emerging companies.
 
Janssen will utilize DCPrime’s DCOne technology in feasibility studies for the development of a dendritic cell-based vaccine for which it will have the option to further develop towards regulatory approval.
 
“DCPrime is always looking for new opportunities for our DCOne technology,” said Marcel Zwaal, chief executive officer of DCPrime. “We are very excited to be able to work with Janssen and it will enable us to further extend the use our vaccine products.”